Chinese Medicine: Subsidiary Lincomycin Hydrochloride Injection Passes Generic Drug Consistency Evaluation.

On September 23, the announcement of China Pharmaceutical Company stated that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., recently received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration for Lincomycin Hydrochloride Injection. The drug has passed the evaluation of generic drug quality and efficacy consistency. Lincomycin Hydrochloride Injection is mainly used for the treatment of severe infections caused by sensitive strains of streptococcus, pneumococcus, and staphylococcus.